Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-Week Extension Phase IIb Study of MK-4618 vs Placebo and Tolterodine in Overactive Bladder
2011-002533-18Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vibegron in overactive bladder (OAB) (3 arms), sponsored by Merck & Co. Primary endpoint: Safety and Tolerability. Started Jun 2011; status: completed.
02
Drugs
vibegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2011-002533-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002533-18.